Revolution Medicines Prioritizes Independence After Merck's Bid

Cancer drugmaker Revolution Medicines announced that a sale is not a priority, pushing back against acquisition attempts. This statement follows an unsuccessful $32 billion bid from Merck, indicating the biotech company's intent to remain independent.